SIRS-Lab and Biosite(R) Incorporated Announce Collaboration to Develop Diagnostics for Sepsis
August 25 2005 - 8:00AM
PR Newswire (US)
JENA, Germany and SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ --
SIRS-Lab GmbH entered into a collaboration agreement with the
U.S.-based bio-medical company, Biosite(R) Incorporated
(NASDAQ:BSTE) for the evaluation and potential commercialization of
sepsis markers. Under the collaboration, SIRS-Lab will provide
access to selected biomarkers for sepsis. Biosite will then make
antibodies to those selected targets using the Company's
proprietary antibody development process, which combines
immunization of mice and phage display to generate highly diverse
libraries of Omniclonal(R) antibodies with high affinity and low
cross-reactivity. The antibodies will be used to generate assays
for the measurement of the selected biomarker targets in blood
samples. Validated biomarkers will then be assessed for
commercialization potential, with high-value markers added to
Biosite's product development process. "We are delighted to work
with Biosite to evaluate the potential value of our sepsis
biomarkers for clinical diagnostic applications," said Dr. Stefan
Rubwurm, SIRS-Lab's chief executive officer. "This agreement
combines the strengths of both companies: Biosite's proven antibody
development and commercialization process for diagnostic products
with our expertise in molecular medicine concerning inflammatory
diseases." "Our Biosite Discovery program is focused on diseases
for which rapid and accurate diagnostic tests are needed. Our
antibody technology allows us to quickly and economically evaluate
potential biomarkers for new tests," said Gunars Valkirs, Ph.D.,
senior vice president Biosite Discovery. "We value SIRS-Lab's
competence in the identification of biomarkers and we are pleased
to have access to their intellectual property in the area of
sepsis." The financial terms of the agreement were not disclosed.
About SIRS-Lab SIRS-Lab, a research driven diagnostics company
located in the BioInstrumentation Center in Jena/Germany, is
focused on the identification, development and commercialization of
novel, proprietary biomarkers. Those biomarkers provide a basis for
the development of diagnostic systems for the early identification
of inflammatory/ immunological host responses as well as for the
early identification of the bacterial causes of infection.
SIRS-Labs mission is the development of new diagnostic systems for
clinical routine diagnostic and therapy monitoring of sepsis and
acute inflammatory diseases. Information on SIRS-Lab can be found
at http://www.sirs-lab.com/. About Biosite Incorporated Biosite
Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis.
The Company's products contribute to improvements in medical care
by aiding physicians in the diagnosis of critical diseases and
health conditions. Biosite's Triage(R) rapid diagnostics are used
in approximately 50 percent of U.S. hospitals and in more than 50
international markets. Information on Biosite can be found at
http://www.biosite.com/. Except for the historical information
presented herein, matters discussed in this press release are
forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by
such statements. Statements that are not historical facts,
including but not limited to statements that are preceded by,
followed by, or that include the words "will"; "believes";
"should"; "intends"; "anticipates"; "plans"; "expects";
"estimates"; or similar statements are forward-looking statements.
Forward looking statements include statements about the potential
benefits of the collaboration and license agreement between Biosite
and SIRS-Lab, Biosite's ability to generate antibody libraries of
selected targets and evaluate the diagnostic utility of the
targets, Biosite's ability to develop and commercialize potential
products based on selected targets and Biosite's ability to
incorporate any licensed targets into its product development
pipeline. Risks that should be considered include risks and
uncertainties regarding the discovery and product development
process generally, risks associated with the introduction of
competitive products from companies with greater capital and
resources, uncertainties around the proprietary nature of the
targets subject to the collaboration, expansion or development of a
direct sales effort in domestic and international markets, and
risks and expenses associated with litigation, contract disputes,
patent conflicts, product recalls, manufacturing constraints,
backlog, delays or inefficiencies, shipment problems, seasonal
customer demand, the timing of significant orders, changes in
reimbursement policies, regulatory changes, competitive pressures
on average selling prices, and the other risks detailed in
Biosite's most recent Annual Report on Form 10-K, as amended,
Quarterly Report on Form 10-Q, and other SEC filings. Biosite
disclaims, any intent or obligation to update these forward-looking
statements. Copies of Biosite's public disclosure filings are
available from its investor relations department. Biosite(R),
Omniclonal(R), Triage(R) and New Dimensions in Diagnosis(R) are
registered trademarks of Biosite Incorporated. The Company's logo
is a trademark of Biosite Incorporated. DATASOURCE: Biosite
Incorporated CONTACT: Roberto C. Wolfer, Manager Business
Development, SIRS-Lab GmbH, +49-0-3641-508-250, or cell,
+49-0-179-788-5452, , or Nadine Padilla VP, Corporate &
Investor Relations, Biosite Incorporated, +1-858-805-2820, Web
site: http://www.biosite.com/ Company News On-Call:
http://www.prnewswire.com/comp/116737.html
Copyright
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Oct 2023 to Oct 2024